{
    "clinical_study": {
        "@rank": "43422", 
        "arm_group": {
            "arm_group_label": "First line WT KRAS mCRC"
        }, 
        "brief_summary": {
            "textblock": "PREMIUM is an observational pharmaco-epidemiologic, transversal, multi-centric, prospective\n      cohort study and with independent investigators. The purpose is to compare PFS in real life\n      with PFS clinical trials and to determine factors impacting efficacy and compliance to\n      cetuximab treatment in first line K-ras wild-type (wt) metastatic colorectal cancer."
        }, 
        "brief_title": "PREMIUM, Observational Study", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "First Line WT KRAS mCRC", 
        "detailed_description": {
            "textblock": "Retrospective studies have shown the influence of some factors on the efficacy of treatment\n      with cetuximab (nicotine, magnesium etc..). No randomized study has compared the mode of\n      administration of weekly and biweekly cetuximab. What are the factors influencing patient\n      compliance? Adverse events, the relation between doctor and patient. PREMIUM will attempt to\n      explore and assess the variables associated with efficacy and compliance to treatment and\n      study practices in France for clinical management."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients > 18 years old diagnosed with mCRC\n\n          -  patients na\u00efve for CT excepted for adjuvant setting or trated max 2 cycles CT in\n             first line mCRC with or without cetuximab\n\n          -  all patients receiving cetuximab in first line treatment associated or not with CT\n\n          -  patients relapsed < 6 months after an adjuvant therapy\n\n        Exclusion Criteria:\n\n          -  patients participating to clinical trials"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "patients from private and public centers"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756625", 
            "org_study_id": "PREMIUM"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cetuximab", 
            "nicotine", 
            "magnesium"
        ], 
        "lastchanged_date": "December 20, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Avignon", 
                    "country": "France", 
                    "state": "Vaucluse", 
                    "zip": "84000"
                }, 
                "name": "Institut Sainte-Catherine"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Factors Impacting on Efficacy and Compliance to Cetuximab Treatment in First Line WT KRAS Metastatic Colorectal Cancer", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France : CCTIRS / CNIL", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To compare PFS rate at 1 year with PFS in clinical studies (ITT and subgroup analysis)", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756625"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Institut Sainte Catherine", 
            "investigator_full_name": "Dr.Laurent Mineur", 
            "investigator_title": "Oncologist", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "ORR at 1 year (ITT and subgroup analysis)", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "Institut Sainte Catherine", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Merck Serono International SA", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "BESPIM, CHU N\u00eemes (data analysis)", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Dr.Laurent Mineur", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2012"
    }
}